抗体-药物结合物的进化:朝着准确的DAR和多特异性发展
Wenge Dong1, Wanqi Wang1, Chan Cao1
1State Key Laboratory of Elemento-Organic Chemistry and Frontiers Science Center for New Organic Matter, College of Chemistry, Nankai University, Tianjin, 300071, China.
ChemMedChem
|May 17, 2024
概括
抗体-药物合物 (ADC) 面临着因药物-抗体比率 (DAR) 和耐药性变化的挑战. 创新侧重于均的DAR和多特异性的设计,以提高向癌症治疗的疗效.
科学领域:
- 在瘤学瘤学.
- 生物技术是生物技术.
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗体-药物合物 (ADC) 通过杆将细胞毒性有效载荷向癌细胞的向输送.
- 关键的限制包括药物对抗体比率 (DAR) 的异质性和获得的耐药性,影响疗效和药理动力学 (PK).
研究的目的:
- 批判性地审查ADC技术当前的挑战.
- 评估同质DAR和多特异性药物设计的创新解决方案,以克服耐药性.
- 为改善治疗结果提供对ADC进展的最新视角.
主要方法:
- 对当前的ADC技术进行文献审查和批判性分析.
- 深入研究实现均DAR的方法.
- 探索针对药物耐药性的多特异性药物的设计策略.
主要成果:
- DAR中的异质性显著影响ADC细胞毒性和PK概况.
- 药物耐药性是临床ADC应用的一个主要障碍.
- 新的策略正在出现,用于精确的DAR控制和多种特异性的ADC开发.
结论:
- 实现均的DAR对于优化ADC性能至关重要.
- 多特异性药物设计为打击ADC耐药性提供了一个有希望的途径.
- 在ADC技术的持续创新对于改善癌症治疗至关重要.
更多相关视频
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
7.6K
07:36Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
5.3K
相关概念视频
Antibody Actions
1.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K
Affinity and Avidity
36.0K
Overview
36.0K
Cross-reactivity
31.0K
Overview
31.0K
Hybridoma Technology
14.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.7K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Antibody Structure
60.1K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
60.1K
